What Happens When You Stop Taking Semaglutide?

When you stop taking semaglutide, the drug clears your body over about 5 to 7 weeks, appetite returns toward where it was before treatment, and most people regain weight. In the largest follow-up study, the STEP 1 extension, people who stopped semaglutide 2.4 mg had regained about two-thirds of the weight they had lost one year later, and improvements in blood pressure and blood sugar faded along with it. Regain is not universal or total: nearly half of those participants were still at least 5% below their starting weight. Stopping is not dangerous in itself, but it should be planned with your prescriber.

What the clinical trials found after people stopped

Two large studies funded by the manufacturer were designed, at least in part, to answer this exact question. Both tested the 2.4 mg weekly weight-management dose in adults with obesity or overweight who did not have diabetes. They are randomized trials, the strongest kind of evidence available, although the follow-up after stopping in one of them was exploratory.

As of September 2026, semaglutide is FDA approved for weight management (as a weekly injection and a once-daily tablet) for long-term weight reduction and for lowering the risk of major cardiovascular events in adults with established heart disease and obesity or overweight, and the injection is also approved for a form of fatty liver disease called MASH. Semaglutide is also approved at lower doses for type 2 diabetes. Every semaglutide label carries a boxed warning about thyroid C-cell tumors, based on rodent studies. The label describes it as a treatment to reduce weight and maintain that reduction long term, which is a clue to what happens when it ends.

The STEP 1 extension: one year off the drug

STEP 1 was the main trial behind the approval of semaglutide for weight management. It enrolled 1,961 adults, who received either semaglutide 2.4 mg or placebo once a week for 68 weeks, along with lifestyle counseling. Average weight loss was 14.9% with semaglutide and 2.4% with placebo.

At week 68, both the drug and the lifestyle program stopped. A subset of 327 participants (228 from the semaglutide group and 99 from the placebo group) agreed to be followed for another year with no study treatment at all. This is the STEP 1 extension, published in Diabetes, Obesity and Metabolism in 2022.

The people in the semaglutide group of this subset had lost an average of 17.3% of their body weight by week 68. Over the following year off treatment, they regained 11.6 percentage points of that. At week 120, their net loss from their original starting weight was 5.6%. The placebo group ended at a net loss of 0.1%. In other words, about two-thirds of the weight lost on semaglutide came back within a year.

The average hides a wide spread. At week 120, 48.2% of the former semaglutide group were still at least 5% below their starting weight, compared with 22.6% of the former placebo group. A 5% loss is a commonly used threshold for clinically meaningful weight loss. So roughly half of people kept a clinically relevant amount of weight off for a year, and roughly half did not.

STEP 4: a randomized withdrawal trial

STEP 4, published in JAMA in 2021, tested withdrawal more directly. All 902 participants started on semaglutide and had the dose raised over 16 weeks, then stayed at 2.4 mg for 4 more weeks. The 803 people who reached the full dose had lost an average of 10.6% of their body weight by week 20.

At that point they were randomly assigned, without knowing which, to keep taking semaglutide (535 people) or to switch to placebo injections (268 people) for another 48 weeks. Both groups kept receiving monthly lifestyle counseling.

From week 20 to week 68, the group that continued semaglutide lost a further 7.9% of body weight. The group switched to placebo regained 6.9%. The gap between the two groups was 14.8 percentage points. Over the whole 68 weeks, the continuing group ended 17.4% below their starting weight and the switched group ended 5.0% below.

Waist size, systolic blood pressure (the top number), and self-reported physical functioning all ended up better in the group that stayed on the drug. Notably, the people who switched to placebo regained weight even though they had continuing lifestyle counseling and did not know their injection had changed. That points to biology, not motivation.

What the pooled evidence says about speed

A systematic review and meta-analysis from the University of Oxford, published in The BMJ in January 2026, pooled 37 studies of weight management medications with 9,341 participants. Across all drugs, people regained an average of 0.4 kg (about 0.9 pounds) per month after stopping.

For the newer drugs, semaglutide and tirzepatide, regain was faster: about 0.8 kg (about 1.8 pounds) per month. At that pace the authors projected a return to starting weight about 1.5 years after stopping. That figure is a projection. Follow-up after stopping these newer drugs was limited, at most about a year, so anything beyond that is extrapolated, and the authors judged only 12 of the included randomized trials to be at low risk of bias, against 18 at high risk.

The same review found that weight came back faster after stopping medication than after ending a diet and exercise program, by about 0.3 kg per month, regardless of how much weight was lost in the first place.

This is a feature of the drug class, not a flaw unique to semaglutide

The same pattern appeared with tirzepatide in the SURMOUNT-4 trial (JAMA, 2024). After 36 weeks on tirzepatide, 670 adults had lost an average of 20.9% of their weight. Those switched to placebo regained 14.0% over the next year, while those who continued lost another 5.5%. If you are comparing the two drugs, regain after stopping is not a reason to choose one over the other. A fuller comparison is in the guide to tirzepatide versus semaglutide.

How to read these numbers honestly

• They are averages. Individual results ranged from full regain, or more, to almost none.
• In the STEP 1 extension, all support ended along with the drug. People who stop with a plan in place may do differently, but that has not been proven in a large trial.
• The extension followed a subset chosen partly by study site, and the authors note this could introduce selection bias. No formal statistical tests were run on the extension data.
• Regain appeared to slow toward the end of the year off treatment. The authors could not tell whether weight was leveling off below the starting point or simply slowing as it approached it.
• Both trials were funded by the manufacturer. Their findings have since been echoed by independent analyses such as the BMJ review.

How long semaglutide stays in your body after the last dose

Semaglutide is built to last. It binds tightly to albumin, a protein in your blood, which protects it from being broken down and filtered out. According to the FDA prescribing information, its elimination half-life is about 1 week, meaning the amount in your blood falls by half roughly every 7 days.

The label states that semaglutide remains in the circulation for about 5 to 7 weeks after the last weekly injection (2.4 mg or 7.2 mg) or the last 25 mg tablet. In practice, the drug's effect does not switch off the day you skip a dose. It fades over a month or more.

What this gradual fade means for you

• Appetite usually does not come roaring back in the first week. Most people notice it returning gradually over several weeks as blood levels fall.
• Drug effects, including slowed stomach emptying and any interaction with other medicines, can persist for weeks after the last dose. This matters for surgery, pregnancy planning, and side effects, all covered below.
• The prescribing information does not describe a withdrawal syndrome, and it does not require tapering for safety. Semaglutide is not known to be habit forming. What people feel after stopping is the return of their own underlying appetite signals.

What happens to your appetite

Semaglutide copies a gut hormone called GLP-1 (glucagon-like peptide-1), which your intestine releases after you eat. GLP-1 receptors sit in several brain regions that regulate appetite, and the label states that semaglutide lowers calorie intake, most likely by acting on appetite. The background is covered in the guide to how GLP-1 weight loss injections work.

How strong the appetite effect is while you take it

In a 20-week randomized study of 72 adults with obesity, people on semaglutide 2.4 mg ate 35% fewer calories at a buffet-style test lunch than people on placebo. They reported less hunger, more fullness, fewer and weaker food cravings, and better control over eating.

An earlier crossover study of 30 adults, using a lower 1.0 mg dose for 12 weeks, found a 24% drop in total calories eaten across a day of test meals, along with a lower preference for high-fat foods. Resting metabolic rate, adjusted for lean body mass, did not differ between semaglutide and placebo. In other words, the drug works mainly by changing how much you want to eat, not by making you burn more.

What returns when the drug is gone

All of that is a drug effect, and it lasts only as long as the drug is present. Once semaglutide clears, there is no evidence that it leaves behind a lasting reset of appetite. People commonly describe the return of what is often called food noise: frequent thoughts about food, stronger cravings, larger portions before feeling full, and hunger returning sooner after a meal.

It is worth being honest about a gap here. No published trial has formally tracked appetite ratings week by week after stopping semaglutide, and the STEP 1 extension did not measure appetite. The description above rests on the known mechanism, the speed of weight regain in trials, and patient reports, not on direct measurement.

Why the weight comes back: the biology

Weight regain after stopping is often read as a personal failure. The evidence points the other way. Your body actively defends its previous weight, and semaglutide had been holding that defense in check.

Your body pushes back against weight loss

The clearest demonstration comes from a 2011 study in the New England Journal of Medicine. Fifty adults with overweight or obesity lost an average of 13.5 kg (about 30 pounds) on a 10-week very low calorie diet. Researchers measured their appetite hormones before the diet, right after it, and again one year later.

After weight loss, levels of leptin, peptide YY, cholecystokinin, and amylin, which are hormones that signal fullness or adequate energy stores, fell. Ghrelin, the main hunger hormone, rose. Participants' own ratings of hunger increased. One year later, most of those hormone changes and the increased hunger were still there. The body had not accepted the new weight as normal.

This was a small study of weight loss by diet, not by medication, so it does not prove the same thing happens after semaglutide. But the STEP 1 extension authors point to exactly these compensatory changes to explain their results, and nothing about losing weight with a drug would be expected to exempt you from them.

The drug treats the condition without curing it

While you take semaglutide, a strong fullness signal from the drug overrides those hunger signals. Remove it and they are unopposed, at a time when you weigh less and your body is pushing to regain. The more weight you have lost, the larger that push tends to be. The STEP 1 extension authors suggest this is one reason regain was brisk in their study: participants had lost more weight than in older drug trials, so they had more to regain.

This is the same logic that applies to blood pressure or cholesterol medication. The pill controls the problem while you take it. Nobody considers it a failure of willpower when blood pressure rises after stopping a blood pressure drug. The researchers behind STEP 1 reached the same conclusion, writing that their findings confirm obesity is a chronic condition and suggest ongoing treatment is needed to maintain the benefits.

What about muscle

The label notes that semaglutide reduces fat mass more than lean mass, but some lean mass is lost with any substantial weight loss. A common worry is that regained weight returns mostly as fat, leaving you with a worse body composition than before. That is biologically plausible, but there is no good published data measuring body composition after semaglutide is stopped, so it remains a concern and not an established fact. It is one more reason strength training features in most maintenance plans.

What happens to blood pressure, blood sugar, and cholesterol

Semaglutide improves several markers of heart and metabolic health, largely because of the weight loss itself. The evidence shows that most of these improvements track your weight: as weight returns, they fade.

Results from the STEP 1 extension

In the former semaglutide group, average systolic blood pressure fell from 129 to 121 mmHg during treatment, then rose to 131 mmHg a year after stopping, back to where it began. Diastolic pressure (the bottom number) followed the same path, from 81 to 78 and back to 82.

HbA1c, a blood test reflecting average blood sugar over about three months, fell from 5.7% to 5.2% on treatment and had climbed to 5.6% a year after stopping. Among participants who had prediabetes at the start, 93.6% had normal blood sugar at week 68. A year after stopping, that had fallen to 43.3%, not far above the 34.0% seen in the former placebo group.

Not everything was lost. C-reactive protein, a marker of inflammation, rose after stopping but remained below its starting level at week 120, and some cholesterol measures also stayed modestly better than baseline. This fits the fact that, on average, a little over 5% of body weight was still off.

What the pooled data project

The 2026 BMJ meta-analysis projected that HbA1c, fasting glucose, blood pressure, total cholesterol, and triglycerides would all return to pre-treatment levels within about 1.4 years of stopping weight management medication. As with weight, this is a projection from shorter follow-up.

If you have type 2 diabetes

Semaglutide lowers blood sugar by boosting insulin release and reducing glucagon when glucose is high. Stop it, and that effect ends as the drug clears, so blood sugar can be expected to rise unless another treatment takes its place. If you take semaglutide for diabetes, stopping it is a decision about your diabetes treatment as a whole and needs a plan from your prescriber in advance.

There is a second, less obvious issue. The label advises that doses of insulin or sulfonylureas (pills that push the pancreas to release insulin) may need to be lowered when semaglutide is started, to avoid low blood sugar. If yours were lowered, they may need to be revisited when semaglutide stops. Do not adjust them on your own.

If you take it for heart protection

In the SELECT trial of 17,604 adults with existing cardiovascular disease and overweight or obesity but no diabetes, semaglutide 2.4 mg reduced heart attack, stroke, and cardiovascular death combined from 8.0% to 6.5% over an average follow-up of about 40 months, a 20% relative reduction. That benefit was measured in people assigned to ongoing treatment. No trial has tested whether any of that protection lasts after the drug is stopped, and given that blood pressure and blood sugar drift back, it would be unwise to assume it does.

How often people stop, and why

If you are thinking about stopping, or already have, you are in the majority. A 2025 study in JAMA Network Open looked at electronic health records for 125,474 US adults with overweight or obesity who started semaglutide, liraglutide, or tirzepatide between 2018 and 2023. Within one year, 64.8% of those without type 2 diabetes had stopped, as had 46.5% of those with type 2 diabetes.

People who lost more weight were less likely to stop, and people who had moderate or severe gastrointestinal side effects were more likely to. Among those who stopped, 36.3% of people without diabetes and 47.3% of people with diabetes had restarted within a year. This was an observational study of health records, so it can show patterns but cannot fully explain motives. Supply shortages during those years, insurance coverage, and cost all plausibly played a part.

Common reasons for stopping include side effects, reaching a goal weight, access problems, planning a pregnancy, an upcoming surgery, or simply not wanting to take a medication indefinitely. Side effects are a frequent one, and many ease with time or slower dose increases, as described in the guide to the semaglutide side effects timeline.

Tapering versus stopping all at once

Many people assume that coming off slowly must protect against regain. It is a reasonable idea, and it is popular online. The evidence for it is thin.

What the label says

The prescribing information contains no instructions to taper. The dose is built up gradually at the start, over 16 weeks, to limit nausea and other gut side effects, but nothing in the label calls for a gradual step-down at the end. Because the drug's half-life is about a week, stopping all at once already produces a slow decline in blood levels over 5 to 7 weeks.

What the research says

The most quoted evidence is a conference abstract presented at the European Congress on Obesity in 2024, from a digital weight management company. Among 2,246 program users, 353 tapered their semaglutide dose over a median of 9 weeks while receiving lifestyle coaching. Average weight was stable during the taper, and the estimated change 26 weeks after stopping entirely was a loss of 1.5%, with a wide margin of error that ran from a 6.4% loss to a 3.3% gain.

That sounds encouraging, but consider its limits. It was not randomized, there was no comparison group that stopped abruptly, the people who tapered had chosen to do so with their clinician and may have been the ones doing best, median follow-up after stopping was under 20 weeks, most of the authors worked for the company running the program, and as of this writing it has been presented as an abstract and not as a full peer-reviewed paper. About 1 in 5 participants had restarted semaglutide within 26 weeks.

Randomized evidence is on the way but does not exist yet. A trial registered on ClinicalTrials.gov (NCT07783854) plans to compare a stepwise semaglutide dose reduction with staying on a steady dose in 72 adults. It was listed as not yet recruiting, with primary results not expected before the end of 2027.

A lower maintenance dose is different from tapering off

Tapering to zero and settling on a lower long-term dose are different things. The current label lists both 2.4 mg (recommended) and 1.7 mg once weekly as maintenance doses for weight reduction, and tells prescribers to consider response and tolerability in choosing between them. (For adults who tolerate 2.4 mg and need more weight reduction, it also allows an increase to a maximum of 7.2 mg once weekly.) Whether doses below 1.7 mg, or injections spaced further apart, can hold weight steady has not been established in randomized trials. This is a conversation to have with your prescriber, not an experiment to run alone.

Maintenance strategies and how strong the evidence is for each

If regain is driven by biology, what can realistically hold it back? Here is what has been studied, in rough order of how strong the evidence is.

Staying on treatment

This is the only strategy proven in large randomized trials. In STEP 4, people who continued semaglutide kept losing weight while those who stopped regained. In STEP 5, a two-year randomized trial of 304 adults, average weight loss with semaglutide was 15.2% at week 104 versus 2.6% with placebo, showing that the effect holds for at least two years of continued use. That does not mean everyone must stay on it for life. It means that, so far, continuing is what the evidence supports for keeping the weight off.

Structured exercise

The best evidence for a non-drug strategy comes from a Danish randomized trial of a related, older GLP-1 drug, liraglutide 3.0 mg daily. After losing an average of 13.1 kg (about 29 pounds) on an 8-week low calorie diet, 195 adults with obesity were assigned for one year to supervised exercise, liraglutide, both, or placebo. The results were published in the New England Journal of Medicine in 2021. The combination held off the most weight and was the only approach that also improved fitness, insulin sensitivity, and HbA1c.

The researchers then followed 109 of the participants for another year after all treatments ended. People who had taken liraglutide alone regained an average of 9.6 kg (about 21 pounds). People who had done supervised exercise alone regained 3.6 kg (about 8 pounds), and those who had done both regained 7.1 kg (about 16 pounds). The odds of still being at least 10% below starting weight were about four times higher in the former combination group than in the former liraglutide-only group.

One likely reason: the exercise habit outlasted the study. A year later, people from the exercise groups reported a median of about 225 to 240 minutes of moderate to vigorous activity per week, versus about 30 minutes in the former liraglutide-only group. The program itself was demanding: supervised, moderate to vigorous exercise sustained for a full year.

The caveats matter. The drug was liraglutide and not semaglutide, the follow-up group was small, and only about two-thirds of those who finished the treatment year returned for it, with better responders more likely to return. Still, it is the most direct evidence that building an exercise routine while on a GLP-1 drug changes what happens after it. If exercise has not moved the scale for you before, the article on working out without losing fat explains why its main value is in maintenance and body composition.

Diet and behavioral support

Here the evidence is sobering. In STEP 4, monthly lifestyle counseling continued after the switch to placebo, and people still regained 6.9%. The BMJ meta-analysis found no significant difference in the rate of regain between studies that offered behavioral support alongside the medication, or after it stopped, and studies that did not.

That does not make nutrition irrelevant. Adequate protein and resistance training are widely recommended to protect muscle during and after weight loss, and the habits you build on the drug are the ones you will rely on later. But no dietary approach has been shown in a trial to prevent regain after semaglutide, and anyone who promises otherwise is going beyond the data.

Restarting, switching, or using a different medication

Restarting is common, as the health records study showed. The current label says that if 2 or more weekly injections in a row are missed, dose escalation should be reinitiated at a lower dose, to reduce the risk of gut side effects. After a gap of several weeks, expect your prescriber to bring you back up gradually and not to resume at your old full dose.

The label also describes switching between the weekly 2.4 mg injection and the daily 25 mg tablet, which may matter if injections are the reason you want to stop. Other options your prescriber may raise include a different anti-obesity medication. None of these sequences has been tested head to head as a maintenance plan after semaglutide.

Side effects after stopping and when restarting

Nausea, vomiting, diarrhea, and constipation are the most common side effects of semaglutide, and they are effects of the drug on the gut. As the drug clears, they would be expected to ease, though with a 5 to 7 week clearance this may be gradual. If gut symptoms persist well after that window, something else may be going on and it is worth a medical visit.

The practical risk runs in the other direction. People who have been off semaglutide for a month or more and then resume at their old full dose, sometimes using leftover pens, can get hit with severe nausea and vomiting because their body is no longer used to it. The label's advice about restarting the escalation exists for this reason. Dehydration from vomiting and diarrhea is also how semaglutide can harm the kidneys, according to the label's warning on acute kidney injury.

While any drug remains in your system, its serious warnings still apply. The label advises stopping and seeking prompt care for suspected pancreatitis, which typically shows up as severe, persistent abdominal pain that may spread to the back, with or without vomiting.

Stopping before surgery or a procedure

Semaglutide slows stomach emptying. The FDA label warns of rare reports of pulmonary aspiration, meaning stomach contents entering the lungs, in people on GLP-1 drugs who were under general anesthesia or deep sedation, even though they had followed standard fasting instructions.

On what to do about it, the label is candid: the available data are insufficient to say whether changing fasting instructions or temporarily stopping the drug reduces the risk. Its one firm instruction is to tell your healthcare providers that you take semaglutide before any planned surgery or procedure.

What the specialist societies advise

In 2023, the American Society of Anesthesiologists suggested holding weekly GLP-1 drugs for a week before elective procedures. In October 2024, a joint guidance from five societies, covering anesthesiology, gastroenterology, and bariatric and endoscopic surgery, moved to a risk-based approach under which most patients can continue their medication.

That guidance lists factors that raise the risk of a full stomach: being in the dose-escalation phase, higher doses, weekly (versus daily) formulations, current gut symptoms such as nausea, vomiting, or constipation, and other conditions that slow the stomach, such as gastroparesis or Parkinson's disease. For people at higher risk it suggests a liquid diet for at least 24 hours before the procedure, an ultrasound check of the stomach where available, and adjusting the anesthesia technique. The anesthesiologists' society release that accompanied it adds that elective surgery should be deferred until the dose-escalation phase has passed and gut side effects have settled.

If a team does decide to hold the drug, the guidance points to the earlier convention: the day of surgery for daily drugs, a week before for weekly ones. It also warns that holding it carries its own costs, including high blood sugar in people with diabetes. Given a 1-week half-life, skipping one dose lowers the drug level but does not clear it.

The bottom line is that this is decided case by case by your surgeon, anesthesiologist, and prescriber together. Do not stop on your own before a procedure, and do not stay silent about taking it. Compounded or online-sourced semaglutide counts too, and anesthesia teams need to know about it.

Stopping before pregnancy

Semaglutide should not be used during pregnancy for weight loss. The label states that weight loss offers no benefit to a pregnant patient and may cause fetal harm. In animal studies (rats, rabbits, and monkeys), exposure during pregnancy was linked to pregnancy loss, structural abnormalities, and growth changes, at exposures near or below human doses, alongside marked maternal weight loss. Human data are too limited to confirm or rule out a risk.

Because the drug lingers, the label instructs that it be discontinued at least 2 months before a planned pregnancy. If a pregnancy is discovered while you are taking it for weight or heart risk, the label says to stop and to tell your doctor. The manufacturer runs a pregnancy exposure registry to gather better data.

What happens to weight during the pregnancy

A 2025 study in JAMA looked at what follows. Using records from one large academic health system, researchers matched 448 pregnancies in women who had a GLP-1 prescription in the 3 years before conception or the first 90 days after it with 1,344 similar pregnancies without one. Most of the women had obesity and about a quarter had diabetes before pregnancy.

The GLP-1 group gained more weight during pregnancy: 13.7 kg versus 10.5 kg on average, a difference of 3.3 kg (about 7 pounds). They were more likely to exceed recommended weight gain (65% versus 49%) and had modestly higher rates of preterm delivery (17% versus 13%), gestational diabetes (20% versus 15%), and high blood pressure disorders of pregnancy (46% versus 36%). There was no difference in cesarean delivery or in babies born large or small for their gestational age.

This was an observational study, and the authors acknowledge that leftover differences between the groups could explain some of the findings. It does not suggest that anyone should stay on semaglutide while pregnant. It does suggest that rebound weight gain can overlap with pregnancy, and that the transition deserves planning with both your prescriber and your obstetric provider. Separately, because semaglutide slows stomach emptying, the label notes it can affect absorption of oral medicines, so ask how this applies to any pills you rely on.

Compounded semaglutide and the supply question

Some people stop because their source of semaglutide changes. During the national shortage, pharmacies were permitted to compound copies of semaglutide. The FDA declared the shortage of semaglutide injection resolved on February 21, 2025, and its enforcement grace periods ended on April 22, 2025 for state-licensed compounding pharmacies and May 22, 2025 for outsourcing facilities.

As of September 2026, the FDA's position is that compounded drugs are not FDA approved, meaning the agency has not reviewed them for safety, effectiveness, or quality. The agency reports having received 990 adverse event reports involving compounded semaglutide as of May 31, 2026, including hospitalizations linked to dosing errors, where patients measured the wrong amount from a vial or providers miscalculated doses. It has also raised concerns about products made with salt forms such as semaglutide sodium or semaglutide acetate, which the agency says differ from the active ingredient in the approved drugs, and about counterfeit semaglutide pens found in the US supply chain.

If your supply is being interrupted, the worst options are abrupt gaps followed by restarting at full dose, or turning to unverified online sellers. Raise it with your prescriber early so that any transition, whether to an approved product, a different medication, or a planned stop, is deliberate. An overview of how prescribed semaglutide treatment is normally structured may help frame that conversation.

Myths versus realities

Myth: once you have lost the weight, your body resets and you can stop

Reality: there is no evidence of a lasting reset. In the STEP 1 extension, two-thirds of lost weight returned within a year on average. Hormone studies after diet-induced weight loss show that hunger signals stay elevated for at least a year.

Myth: everyone regains everything

Reality: a year after stopping, the former semaglutide group was still 5.6% below starting weight on average, and 48.2% had kept off at least 5%. Predictions of full regain by about 18 months come from projections, not from direct observation.

Myth: regain means you did not try hard enough

Reality: in STEP 4, participants regained weight despite ongoing monthly counseling and without knowing they had been switched to placebo. Returning appetite is a physiological response, not a character flaw.

Myth: stopping causes withdrawal or is dangerous

Reality: the label describes no withdrawal syndrome, and semaglutide is not known to be habit forming. The real medical risks of stopping are indirect: rising blood sugar in people with diabetes, the return of weight-related health problems, and side effects from restarting at too high a dose.

Myth: the health benefits stay even if the weight returns

Reality: blood pressure returned to baseline and most of the blood sugar improvement was lost a year after stopping in the STEP 1 extension. A few markers, such as C-reactive protein, stayed partly improved, in line with the weight that stayed off.

Questions to ask your prescriber before you stop

• Given my health conditions, what are the specific risks of stopping for me, beyond weight regain?
• If I take insulin, a sulfonylurea, or blood pressure medication, will any doses need adjusting when I stop, and who will monitor that?
• Would a lower maintenance dose be reasonable to try before stopping completely?
• Which numbers should be rechecked after I stop, such as weight, blood pressure, HbA1c, or cholesterol, and when?
• How much regain, or what change in lab results, should prompt us to talk about restarting?
• If I restart after a break, what dose should I begin at?
• I have surgery or a procedure coming up. Should I continue, hold a dose, or change my fasting instructions, and has the anesthesia team been told?
• I am planning a pregnancy. When should I stop, what contraception should I use until then, and how should my weight be managed in the meantime?
• What should an exercise and nutrition plan look like for me now, while the medication is still helping, so that it is a habit before I stop?

The broader point is that stopping works best as a planned step within a longer approach to medical weight loss, not as something that happens when a prescription runs out.

When to seek medical care after stopping

Stopping semaglutide rarely causes an emergency, but a few situations call for prompt attention.

• If you have diabetes: marked thirst, frequent urination, blurred vision, or home glucose readings well above your usual range. Seek urgent care for very high readings with nausea, vomiting, abdominal pain, confusion, or rapid breathing.
• If you take insulin or a sulfonylurea: shakiness, sweating, confusion, or other signs of low blood sugar, especially if your eating pattern is changing.
• In the weeks while the drug is clearing: severe, persistent abdominal pain with or without vomiting, which can signal pancreatitis or gallbladder disease, both listed in the label's warnings.
• After restarting: vomiting or diarrhea severe enough that you cannot keep fluids down, since dehydration can injure the kidneys.
• At any point: signs of a serious allergic reaction, such as swelling of the face, lips, or throat, or trouble breathing.

This is general information, not medical advice. Whether a treatment is right for you is determined by a licensed provider after an evaluation.